Revenue

CanTex Capital's landmark sale of a 1.3M sq ft portfolio to Partners Group highlights booming demand for DFW's strategic shallow bay industrial assets.

An expanded partnership aims to move businesses from AI experimentation to autonomous operations, tackling the critical 'last-mile problem' of value realization.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Metazoa's new Intelligent Assistant for Salesforce goes beyond diagnostics, promising to actively help admins and developers remediate org complexity.

Hundreds of thousands of U.S.-born children live in exile after parental deportation. A new initiative aims to restore their rights and build a path home.

Amid financial headwinds, radiation therapy firm Accuray appoints a proven sales leader to spearhead a critical commercial transformation.

With its public debut on the horizon, S&P Global Mobility hires a seasoned expert in corporate separations to lead its financial structuring.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

Digital health leader Bunny Ellerin joins Aegis Ventures as Chief Ecosystem Officer, a strategic move to fuel AI-native innovation through network power.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

The Permian energy solutions provider is raising $390 million to pay down existing debt and fund a major expansion of its distributed power business.

With a $5M private placement, Ubercrete is one step closer to a public listing and revolutionizing the construction industry with its advanced concrete tech.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

Grubhub is offering a $100K 'Fee Return' to ease tax season stress, but is it real relief or a clever ploy in the competitive food delivery wars?

With 96% participation in a key debt exchange, the mining giant sidesteps a costly clause from its New Gold acquisition, showcasing shrewd financial strategy.

A key summit will dissect Vietnam's plan to navigate US tariffs and Mideast conflict while pursuing its ambitious goal of becoming a high-income nation.

Amidst rising costs and market volatility, Centene appoints two new Group Presidents. Is this strategic overhaul the key to future growth and profitability?